Omega-3 Solutions for Pharmaceuticals


Leading the prescription omega-3 market

Pioneers in the development of prescription omega-3 substances

BASF pioneered the omega-3 pharma market by introducing, in 1994, Omacor®/Lovaza as the first prescription omega-3 drug with approval from the FDA/EU. We became world leaders in high-concentrate omega-3 fatty acids for pharmaceuticals.

In addition to our established & proven high-quality omega-3 product and service portfolio, we offer unrivalled experience and unique expertise in development and management of customized omega-3 solutions.

Why BASF Omega-3 Pharma?

  • More than 100,000 patients included in clinical trials world-over
  • Our Global Safety Database covers 9 million patient years
  • More than 1400 metric tonnes of BASF prescription omega-3s used worldwide annually
  • Our prescription omega-3 (Lovaza™) has been on the top 50 list of most sold pharmaceuticals in the US

Proven, pure and potent omega-3 solutions.

Download Center

Looking for application guides, technical and scientific posters, brochures or technical information? Visit our Download Center.


20 years of experience in pharma

Value-Chain Management

Trusted collaboration with our partners

Regulatory Affairs

Dedicated to omega-3

Sustainability & Traceability

Our product – made from fish oil – can be traced along the entire value chain, back to healthy fish stocks

Pharma Solutions portfolio

Further Solutions